CD8A and melanoma: In a phase IIa clinical study in stage III-IV melanoma patients, Imiquimod in combination with the MelQbG10 vaccine, which contains virus-like nanoparticles loaded with the TLR9 agonist CpG and Melan-A/MART-1 peptide, led to an increase in the frequency of central memory CD8+ T cells (80).